Behçet's disease: 2026 so far

Controlled trial evidence emerged for ulcer reduction over 12 weeks.

In the months covered, two placebo-controlled trials reported fewer oral ulcers and less mouth pain over 12 weeks: a phase 2 trial (a mid-stage trial testing whether a treatment works and is safe) of mufemilast and a phase 2 randomized, double-blind trial (participants are assigned by chance, and neither side knows which treatment was given) of low-dose interleukin-2. The low-dose interleukin-2 trial also reported better quality of life and no infections during the trial, with mostly mild injection-site reactions. Together, these reports add higher-quality short-term evidence for ulcer symptom control, but they did not establish how long benefits last or how these options compare with standard treatments.

Research covered in: February 2026, September 2026

Evidence clustered by organ: uveitis, gut disease, and refractory cases.

From January 2026 to September 2026, several non-randomized datasets suggested that treatment response often depends on which organs are involved, rather than Behcet acting like one single, uniform condition. For uveitis (eye inflammation), a real-world retrospective comparison (a look back at medical records) found tofacitinib and adalimumab had no significant overall differences, while an exploratory subgroup suggested lower response with tofacitinib in central occlusive retinal vasculitis (a severe form of retinal blood vessel inflammation). A prospective Behcet-related uveitis cohort reported improved outcomes on adalimumab, although some patients stopped because of systemic infection; a separate retrospective cohort of non-infectious uveitis from several causes, including Behcet disease, reported improved average vision and lower steroid use, but relapses were common when doses were spaced farther apart. For intestinal and refractory disease (disease that has not responded to prior treatments), small uncontrolled studies and case reports described clinical and endoscopic improvement (symptoms and scope findings) with upadacitinib in anti-TNF-refractory intestinal Behcet disease and improved overall control in refractory Behcet syndrome, but without comparison groups. In these months, the most useful treatment information mainly came in organ-specific, real-world reports, which can guide discussions but do not provide the certainty of randomized comparisons.

Research covered in: February 2026, March 2026, May 2026, June 2026, July 2026, September 2026

Pooled and real-world data supported vascular response, with safety reporting uneven.

In the months covered, anti-TNF therapy remained a central treatment theme for vascular Behcet disease (blood vessel involvement), with support mainly from pooled observational evidence and real-world cohorts. A meta-analysis (a study that combines results across studies) reported a high pooled complete vascular response rate for infliximab in severe/refractory vascular disease, but noted high between-study variability and uneven safety reporting. A separate retrospective cohort comparing first anti-TNF choice found similar initial remission rates for infliximab and adalimumab, with different organ-specific patterns and no severe events reported in that cohort. Additional cohort and case-based reports emphasized that immunosuppressive therapy (medicines that dampen the immune system) alongside corticosteroids was linked to fewer vascular relapses in one clinic cohort, while anticoagulation alone (blood thinners) did not appear to reduce relapses there. These reports support anti-TNF use as a commonly described approach when blood vessels are involved, while leaving uncertainty about which option is best and how safe they are in direct comparison because the evidence was not randomized and safety reporting was inconsistent.

Research covered in: January 2026, May 2026

Real-world studies tested formulation changes and add-ons for mucocutaneous control.

Two practical, non-randomized medication-use strategies were highlighted in the months covered for mucocutaneous/joint symptoms (skin and mouth/genital symptoms, and joint symptoms). A retrospective review reported improved disease activity measures after switching colchicine preparations in people not doing well on the original form, though some discontinued due to adverse events or lack of effect. A larger retrospective cohort reported fewer early oral/genital ulcer recurrences when total glucosides of paeony were added to colchicine, but diarrhea was much more common with the combination during the first three months. In these reports, the main value is setting expectations about possible symptom changes and side effects when adjusting commonly used medicines, without proving that the medication change alone caused the outcomes.

Research covered in: January 2026, August 2026

Monitoring shifted toward organ-targeted tests and imaging consensus.

Monitoring work in the months covered focused on matching the test to the organ involved, rather than relying on one general measure for everyone. For intestinal involvement, an intestinal ultrasound score (a scoring system based on ultrasound images) separated active from inactive ileocecal ulcers versus colonoscopy in development and small validation groups, and fecal calprotectin (a stool marker of gut inflammation) tracked endoscopic activity better than CRP (C-reactive protein, a blood marker of inflammation) in one intestinal Behcet cohort. Later work added exploratory stool NGAL (neutrophil gelatinase-associated lipocalin, a protein measured in stool) as a possible marker of intestinal involvement. For uveitis, an international expert group agreed on a short list of eye imaging tests most relevant for tracking active inflammation and complications, and other studies explored additional eye-derived indices. For Neuro-Behcet (nervous system involvement), an exploratory vessel-wall MRI approach (MRI that looks at the blood vessel wall) found artery wall enhancement only during attack periods in a small pilot study. Overall, these studies point toward organ-targeted monitoring (stool markers, ultrasound, eye imaging, specialized MRI) to better match testing to the symptoms and organs affected.

Research covered in: January 2026, March 2026, August 2026, September 2026